Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) Research & Development (2020 - 2025)

Historic Research & Development for Rapid Micro Biosystems (RPID) over the last 6 years, with Q3 2025 value amounting to $3.5 million.

  • Rapid Micro Biosystems' Research & Development fell 221.67% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year decrease of 501.62%. This contributed to the annual value of $14.6 million for FY2024, which is 1386.12% up from last year.
  • As of Q3 2025, Rapid Micro Biosystems' Research & Development stood at $3.5 million, which was down 221.67% from $3.2 million recorded in Q2 2025.
  • Rapid Micro Biosystems' 5-year Research & Development high stood at $3.8 million for Q1 2024, and its period low was $2.1 million during Q1 2021.
  • Its 5-year average for Research & Development is $3.2 million, with a median of $3.2 million in 2023.
  • As far as peak fluctuations go, Rapid Micro Biosystems' Research & Development skyrocketed by 8786.17% in 2021, and later tumbled by 1372.86% in 2025.
  • Rapid Micro Biosystems' Research & Development (Quarter) stood at $2.9 million in 2021, then rose by 19.19% to $3.4 million in 2022, then fell by 2.5% to $3.3 million in 2023, then increased by 2.53% to $3.4 million in 2024, then increased by 3.73% to $3.5 million in 2025.
  • Its Research & Development stands at $3.5 million for Q3 2025, versus $3.2 million for Q2 2025 and $3.6 million for Q1 2025.